Abstract
Cardiac syndrome X is defined as the occurrence of typical chest pain and evidence of myocardial ischemia on noninvasive stress tests (mainly, ST-segment depression during exercise stress test), in the presence of normal coronary arteries at angiography and in the absence of any other cardiac diseases. This condition is now mainly defined as primary microvascular angina (MVA). Abnormalities of endothelium-dependent and endothelium-independent coronary microvascular dilation have been described in many studies, using different invasive and noninvasive methods. An increased coronary microvascular constriction is also involved. The causes of the coronary microvascular dysfunction are likely multiple and may include common cardiovascular risk factors, an abnormal cardiac adrenergic function, insulin resistance, inflammation and, in women, estrogen deficiency. Prognosis is good, but quality of life can significantly be impaired in 10–20 % of patients. Treatment includes classical anti-ischemic drugs and several other pharmacological and nonpharmacological therapeutic tools for those with symptoms refractory to standard antianginal and anti-ischemic therapy.
Keywords
- Coronary Flow Reserve
- Coronary Blood Flow
- Obstructive Coronary Artery Disease
- Exercise Stress Test
- Normal Coronary Artery
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- Cardiac syndrome X:
-
Clinical picture characterized by (1) Typical exercise-induced angina (2) Positive exercise stress test (3) Normal coronary arteries (4) No specific cardiac or systemic diseases
- Microvascular angina (MVA):
-
Angina caused by abnormalities in coronary microcirculation
- Primary MVA:
-
MVA occurring in the absence of any specific cardiac or systemic disease
- Secondary MVA:
-
MVA occurring in the context of specific cardiac or systemic disease (e.g., cardiomyopathy, autoimmune disease, etc.)
- Stable MVA:
-
MVA presenting with a stable (chronic) clinical pattern (mainly exercise-induced angina)
- Unstable MVA:
-
MVA presenting with an acute and/or worsening clinical pattern, usually compatible with a non-ST-segment elevation acute coronary syndrome
References
Albertsson PA, Emanuelsson H, Milsom I (1996) Beneficial effect of treatment with transdermal estradiol-17-beta on exercise-induced angina and ST segment depression in syndrome X. Int J Cardiol 54:13–20
Anderson GL, Limacher M, Assaf AR, Women's Health Initiative Steering Committee et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712
Antonios TF, Kaski JC, Hasan KM, Brown SJ, Singer DR (2001) Rarefaction of skin capillaries in patients with anginal chest pain and normal coronary arteriograms. Eur Heart J 22:1144–1148
Antony I, Lerebours G, Nitenberg A (1995) Loss of flow-dependent coronary artery dilatation in patients with hypertension. Circulation 91:1624–1628
Asbury EA, Slattery C, Grant A, Evans L, Barbir M, Collins P (2008) Cardiac rehabilitation for the treatment of women with chest pain and normal coronary arteries. Menopause 15:454–460
Beltrame JF, Limaye SB, Horowitz JD (2002) The coronary slow flow phenomenon: a new coronary microvascular disorder. Cardiology 97:197–202
Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD (2003) Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J 146:84–90
Borer JS, Fox K, Jaillon P, Lerebours G, for the Ivabradine Investigators Group (2003) Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina. A randomized, double blind, multicentered, placebo-controlled trial. Circulation 107:817–823
Bøtker HE, Moller N, Schmitz O, Bagger JP, Nielsen TT (1997) Myocardial insulin resistance in patients with syndrome X. J Clin Invest 100:1919–1927
Bøtker HE, Sonne HS, Schmitz O, Nielsen TT (1998) Effects of doxazosin on exercise-induced angina pectoris, ST-segment depression, and insulin sensitivity in patients with syndrome X. Am J Cardiol 82:1352–1356
Bøttcher M, Bøtker HE, Sonne H, Nielsen TT, Czernin J (1999) Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with syndrome X. Circulation 99:1795–1801
Boudoulas H, Cobb TC, Leighton RF, Wilt SM (1974) Myocardial lactate production in patients with angina-like chest pain and angiographically normal coronary arteries and left ventricle. Am J Cardiol 34:501–505
Buchthal SD, den Hollander JA, Merz CN et al (2000) Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 342:829–835
Buffon A, Rigattieri S, Santini SA et al (2000) Myocardial ischemia-reperfusion damage after pacing-induced tachycardia in patients with cardiac syndrome X. Am J Physiol Heart Circ Physiol 279:H2627–H2633
Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G (2004) Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 109:2518–2523
Bugiardini R, Manfrini O, De Ferrari GM (2006) Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 166:1391–1395
Camici P, Marracini P, Gistri R et al (1994) Adrenergically mediated coronary vasoconstriction in patients with syndrome X. Cardiovasc Drugs Ther 8:221–226
Cannon RO 3rd, Watson RM, Rosing DR, Epstein SE (1983) Angina caused by reduced vasodilator reserve of the small coronary arteries. J Am Coll Cardiol 1:1359–1373
Cannon RO, Watson RM, Rosing DR, Epstein SE (1985) Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am J Cardiol 56:242–246
Cannon RO 3rd, Quyyumi AA, Schenke WH et al (1990) Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. J Am Coll Cardiol 16:1359–1366
Cannon RO 3rd, Schenke WH, Quyyumi A, Bonow RO, Epstein SE (1991) Comparison of exercise testing with studies of coronary flow reserve in patients with microvascular angina. Circulation 83:III77–III81
Cannon RO, Camici PG, Epstein SE (1992) Pathophysiological dilemma of syndrome X. Circulation 85:883–892
Cannon RO 3rd, Quyyumi AA, Mincemoyer R et al (1994) Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 330:1411–1417
Cemin R, Erlicher A, Fattor B, Pitscheider W, Cevese A (2008) Reduced coronary flow reserve and parasympathetic dysfunction in patients with cardiovascular syndrome X. Coron Artery Dis 19:1–7
Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM (1993a) Effect of hyperventilation and mental stress on coronary blood flow in syndrome X. Br Heart J 69:516–524
Chauhan A, Petch MC, Schofield PM (1993b) Effect of oesophageal acid instillation on coronary blood flow. Lancet 341:1309–1310
Chauhan A, Mullins PA, Thuraisingham SI, Petch MC, Schofield PM (1993c) Clinical presentation and functional prognosis in syndrome X. Br Heart J 70:346–351
Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM (1997) Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. Eur Heart J 18:60–68
Chen JW, Lee WL, Hsu NW et al (1997) Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol 80:32–38
Chen JW, Hsu NW, Wu TC et al (2002) Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 90:974–982
Conti E, Andreotti F, Sestito A et al (2002) Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol 89:973–975
Cosin-Sales J, Pizzi C, Brown S, Kaski JC (2003) C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 41:1468–1474
Cox ID, Hann CM, Kaski JC (1998) Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J 19:250–254
Cox ID, Bøtker HE, Bagger JP, Sonne HS, Kristensen BO, Kaski JC (1999) Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. J Am Coll Cardiol 34:455–460
Crake T, Canepa-Anson R, Shapiro L, Poole-Wilson PA (1988) Continuous recording of coronary sinus oxygen saturation during atrial pacing in patients with coronary artery disease or with syndrome X. Br Heart J 59:31–38
Crea F, Pupita G, Galassi AR et al (1990) Role of adenosine in pathogenesis of anginal pain. Circulation 81:164–172
Czernin J, Sun K, Brunken R, Böttcher M, Phelps M, Schelbert H (1995) Effect of acute and long-term smoking on myocardial blood flow and flow reserve. Circulation 91:2891–2897
De Candia E, Lanza GA, Romagnoli E et al (2005) Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. Int J Cardiol 100:371–376
Dean D, Jones CJ, Hutchison SJ, Peters JR, Henderson AH (1991) Hyperinsulinaemia and microvascular angina (“syndrome X”). Lancet 337:456–457
Demir H, Kahraman G, Isgoren S, Tan YZ, Kilic T, Berk F (2008) Evaluation of post-stress left ventricular dysfunction and its relationship with perfusion abnormalities using gated SPECT in patients with cardiac syndrome X. Nucl Med Commun 29:208–214
Di Franco A, Lanza GA, Di Monaco A et al (2012) Coronary microvascular function and cortical pain processing in patients with silent positive exercise testing and normal coronary arteries. Am J Cardiol 109:1705–1710
Di Monaco A, Lanza GA, Bruno I et al (2010) Usefulness of impairment of cardiac adrenergic nerve function to predict outcome in patients with cardiac syndrome X. Am J Cardiol 106:1813–1818
Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A (1993) Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 328:1659–1664
Elliott PM, Krzyzowska-Dickinson K, Calvino R, Hann C, Kaski JC (1997) Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X). Heart 77:523–526
Emdin M, Picano E, Lattanzi F, L'Abbate A (1989) Improved exercise capacity with acute aminophylline administration in patients with syndrome X. J Am Coll Cardiol 14:1450–1453
Fábián E, Varga A, Picano E, Vajo Z, Rónaszéki A, Csanády M (2004) Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol 94:652–655
Ferrini D, Bugiardini R, Galvani M et al (1986) Opposing effects of propranolol and diltiazem on the angina threshold during an exercise test in patients with syndrome X. G Ital Cardiol 16:224–231
Fragasso G, Chierchia SL, Pizzetti G et al (1997) Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade. Heart 77:32–39
Galassi AR, Kaski JC, Pupita G, Vejar M, Crea F, Maseri A (1989) Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X. Am J Cardiol 64:264–269
Galassi AR, Kaski JC, Crea F et al (1991) Heart rate response during exercise testing and ambulatory ECG monitoring in patients with syndrome X. Am Heart J 122:458–463
Galassi AR, Crea F, Araujo LI et al (1993) Comparison of regional myocardial blood flow in syndrome X and one-vessel coronary artery disease. Am J Cardiol 72:134–139
Galiuto L, Iliceto S (1998) Myocardial contrast echocardiography in the evaluation of viable myocardium after acute myocardial infarction. Am J Cardiol 81:29G–32G
Galiuto L, De Caterina AR, Porfidia A et al (2010) Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in Apical Ballooning or Tako-Tsubo syndrome. Eur Heart J 31:1319–1327
Greenberg MA, Grose RM, Neuburger N, Silverman R, Strain JE, Cohen MV (1987) Impaired coronary vasodilator responsiveness as a cause of lactate production during pacing-induced ischemia in patients with angina pectoris and normal coronary arteries. J Am Coll Cardiol 9:743–751
Gulati M, Cooper-DeHoff RM, McClure C et al (2009) Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 169:843–850
Harrison DG, Bates JN (1993) The nitrovasodilators: new ideas about old drugs. Circulation 87:1461–1467
Jespersen L, Hvelplund A, Abildstrøm SZ et al (2012) Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J 33:734–744
Jhund PS, Dawson N, Davie AP et al (2001) Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. J Am Coll Cardiol 37:1367–1373
Kaski JC, Rosano G, Gavrielides S, Chen L (1994) Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 23:652–657
Kaski JC, Elliott PM, Salomone O et al (1995a) Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 74:620–624
Kaski JC, Rosano GMC, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA (1995b) Cardiac syndrome X: clinical characteristics and left ventricular function: long-term follow-up study. J Am Coll Cardiol 25:807–814
Kaul S, Newell JB, Chesler DA, Pohost GM, Okada RD, Boucher CA (1986) Quantitative thallium imaging findings in patients with normal coronary angiographic findings and in clinically normal subjects. Am J Cardiol 57:509–512
Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I (2003) Benefits of statin treatment in cardiac syndrome-X. Eur Heart J 24:1999–2005
Keating GM (2008) Ranolazine: a review of its use in chronic stable angina pectoris. Drugs 68:2483–2503
Kronhaus KD, Lawson WE (2009) Enhanced external counterpulsation is an effective treatment for syndrome X. Int J Cardiol 135:256–257
Lamendola P, Lanza GA, Spinelli A et al (2010) Long-term prognosis of patients with cardiac syndrome X. Int J Cardiol 140:197–199
Lanza GA (2007) Cardiac syndrome X: a critical overview and future perspectives. Heart 93:159–166
Lanza GA, Crea F (2002) The complex link between brain and heart in cardiac syndrome X. Heart 88:328–330
Lanza GA, Crea F (2010) Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 121:2317–2325
Lanza GA, Manzoli A, Bia E, Crea F, Maseri A (1994) Acute effects of nitrates on exercise testing in patients with syndrome x. Clinical and pathophysiological implications. Circulation 90:2695–2700
Lanza GA, Giordano AG, Pristipino C et al (1997a) Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [123I]metaiodobenzylguanidine myocardial scintigraphy. Circulation 96:821–826
Lanza GA, Gaspardone A, Pasceri V et al (1997b) Effects of bamiphylline on exercise testing in patients with syndrome X. G Ital Cardiol 27:50–54
Lanza GA, Lüscher TF, Pasceri V et al (1999a) Effects of atrial pacing on arterial and coronary sinus endothelin-1 levels in syndrome X. Am J Cardiol 84:1187–1191
Lanza GA, Colonna G, Pasceri V, Maseri A (1999b) Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 84:854–856
Lanza GA, Andreotti F, Sestito A, Sciahbasi A, Crea F, Maseri A (2001) Platelet aggregability in cardiac syndrome X. Eur Heart J 22:1924–1930
Lanza GA, Sestito A, Iacovella S et al (2003) Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation 107:1378–1382
Lanza GA, Sestito A, Cammarota G et al (2004) Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol 94:40–44
Lanza GA, Buffon A, Sestito A et al (2008) Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol 51:466–472
Lanza GA, Camici PG, Galiuto L et al (2013) Methods to investigate coronary microvascular function in clinical practice. J Cardiovasc Med (Hagerstown) 14:1–18
Leonardo F, Fragasso G, Rossetti E et al (1999) Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. Cardiologia 44:1065–1069
Mangieri E, Macchiarelli G, Ciavolella M et al (1996) Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 37:375–381
Maseri A, Crea F, Kaski JC, Crake T (1991) Mechanisms of angina pectoris in syndrome X. J Am Coll Cardiol 17:499–506
Meeder JG, Blanksma PK, Crijns HJ et al (1995) Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability. Eur Heart J 16:1571–1577
Mehta PK, Goykhman P, Thomson LE et al (2011) Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging 4:514–522
Mohri M, Koyanagi M, Egashira K et al (1998) Angina pectoris caused by coronary microvascular spasm. Lancet 351:1165–1169
Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A (2003) Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 41:15–19
Montorsi P, Cozzi S, Loaldi A et al (1990) Acute coronary vasomotor effects of nifedipine and therapeutic correlates in syndrome X. Am J Cardiol 66:302–307
Mosseri M, Yarom R, Gotsman MS, Hasin Y (1986) Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 74:964–972
Motz W, Vogt M, Rabenau O, Scheler S, Lückhoff A, Strauer BE (1991) Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol 68:996–1003
Nadazdin A, Shahi M, Foale RA (1991) Impaired left ventricular filling during ST-segment depression provoked by dipyridamole infusion in patients with syndrome X. Clin Cardiol 14:821–826
Nalbantgil I, Onder R, Altintig A et al (1998) Therapeutic benefits of cilazapril in patients with syndrome X. Cardiology 89:130–133
Nalbantgil S, Altinti A, Yilmaz H, Nalbantgil II, Önder R (1999) The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol 8:40–43
Nihoyannopoulos P, Kaski JC, Crake T, Maseri A (1991) Absence of myocardial dysfunction during stress in patients with syndrome X. J Am Coll Cardiol 18:1463–1470
Ong P, Athanasiadis A, Mahrholdt H, Borgulya G, Sechtem U, Kaski JC (2012) Increased coronary vasoconstrictor response to acetylcholine in women with chest pain and normal coronary arteriograms (cardiac syndrome X). Clin Res Cardiol 101:673–681
Opherk D, Zebe H, Weihe E et al (1981) Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms. Circulation 63:817–825
Ozçelik F, Altun A, Ozbay G (1999) Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X. Clin Cardiol 22:361–365
Panting JR, Gatehouse PD, Yang GZ et al (2002) Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 346:1948–1953
Panza JA, Laurienzo JM, Curiel RV et al (1997) Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography. J Am Coll Cardiol 29:293–301
Pasceri V, Lanza GA, Buffon A, Montenero AS, Crea F, Maseri A (1998) Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. J Am Coll Cardiol 31:62–66
Pizzi C, Manfrini O, Fontana F, Bugiardini R (2004) Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X: role of superoxide dismutase activity. Circulation 109:53–58
Potts SG, Lewin R, Fox KAA, Johnstone EC, Cay EL (1999) Group psychological treatment for chest pain with normal coronary arteries: a controlled trial. QJM 92:81–86
Radice M, Giudici V, Marinelli G (1995) Long-term follow-up in patients with positive exercise test and angiographically normal coronary arteries (syndrome X). Am J Cardiol 75:620–621
Radice M, Giudici V, Pusineri E et al (1996) Different effects of acute administration of aminophylline and nitroglycerin on exercise capacity in patients with syndrome X. Am J Cardiol 78:88–90
Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC (2013) Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 6:660–667
Richardson PJ, Livesley B, Oram S, Olsen EG, Armstrong P (1974) Angina pectoris with normal coronary arteries: transvenous myocardial biopsy in diagnosis. Lancet 2:677–680
Romeo F, Gaspardone A, Ciavolella M, Gioffrè P, Reale A (1988) Verapamil versus acebutolol for syndrome X. Am J Cardiol 62:312–313
Romeo F, Rosano GM, Martuscelli E, Lombardo L, Valente A (1993) Long-term follow-up of patients initially diagnosed with syndrome X. Am J Cardiol 71:669–673
Rosano GM, Collins P, Kaski JC, Lindsay DC, Sarrel PM, Poole-Wilson PA (1995) Syndrome X in women is associated with oestrogen deficiency. Eur Heart J 16:610–614
Rosano GMC, Peters NS, Lefroy D et al (1996) Symptomatic response to 17b-estradiol in women with syndrome X. J Am Coll Cardiol 28:1500–1505
Rosen SD, Lorenzoni R, Kaski JC, Foale RA, Camici PG (1999) Effect of alpha1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X. J Cardiovasc Pharmacol 34:554–560
Rosen SD, Paulesu E, Wise RJ, Camici PG (2002) Central neural contribution to the perception of chest pain in cardiac syndrome X. Heart 87:513–519
Russo G, Di Franco A, Lamendola P et al (2013) Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther 27:229–234
Scalone G, De Caterina A, Leone AM et al (2013) Effect of exercise on circulating endothelial progenitor cells in patients with microvascular angina. Circ J 77:1777–1782
Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE (1993) Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 88:993–1003
Sestito A, Lanza GA, Di Monaco A et al (2001) Relation between cardiovascular risk factors and coronary microvascular dysfunction in cardiac syndrome X. J Cardiovasc Med 12:322–327
Sgueglia GA, Sestito A, Spinelli A et al (2007) Long-term follow-up of patients with cardiac syndrome X treated by spinal cord stimulation. Heart 93:591–597
Shapiro LM, Crake T, Poole-Wilson PA (1988) Is altered cardiac sensation responsible for chest pain in patients with normal coronary arteries? Clinical observations during cardiac catheterization. Br Med J 296:170–171
Shmilovich H, Deutsch V, Roth A, Miller H, Keren G, George J (2007) Circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart 93:1071–1076
Sütsch G, Oechslin E, Mayer I, Hess OM (1995) Effect of diltiazem on coronary flow reserve in patients with microvascular angina. Int J Cardiol 52:135–143
The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators (1997) A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336:1621–1628
Valeriani M, Sestito A, Le Pera D et al (2005) Abnormal cortical pain processing in patients with cardiac syndrome X. Eur Heart J 26:975–982
Villano A, Di Franco A, Nerla R et al (2013) Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol 112:8–13
Yamabe H, Namura H, Yano T et al (1995) Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Cardiovasc Drugs Ther 9:755–761
Yokoyama I, Murakami T, Ohtake T et al (1996) Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med 37:1937–1942
Yoshio H, Shimizu M, Kita Y et al (1995) Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X. J Am Coll Cardiol 25:147–151
Further Reading
Lanza GA, Parrinello R, Figliozzi S (2014) Management of microvascular angina pectoris. Am J Cardiovasc Drugs 14(1):31–40
Lanza GA, Crea F (2014) Acute coronary syndromes without obstructive coronary atherosclerosis: the tiles of a complex puzzle. Circ Cardiovasc Interv 7(3):278–281
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Lanza, G.A., Parrinello, R., Figliozzi, S. (2015). Cardiac Syndrome X and Microvascular Angina. In: Lanzer, P. (eds) PanVascular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37078-6_63
Download citation
DOI: https://doi.org/10.1007/978-3-642-37078-6_63
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-37077-9
Online ISBN: 978-3-642-37078-6
eBook Packages: MedicineReference Module Medicine